Lupus clinical trials at UC Irvine
4 in progress, 3 open to eligible people
Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2)
open to eligible people ages 12 years and up
The trial will evaluate efficacy, safety and tolerability of ianalumab compared to placebo, given as monthly subcutaneous (s.c.) injection on top of standard-of-care (SoC) treatment in participants with active systemic lupus erythematosus (SLE).
Irvine, California and other locations
RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
open to eligible people ages 18-65
RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
Orange, California and other locations
Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis
open to eligible people ages 18 years and up
This trial will evaluate efficacy, safety, and tolerability of subcutaneous (s.c.) ianalumab given every 4 weeks (q4w) or every 12 weeks (q12w) compared to placebo, in combination with SoC, in adult participants with active LN
Orange, California and other locations
VIBRANT: VIB4920 for Active Lupus Nephritis
Sorry, not currently recruiting here
This is a multi-center double-blind placebo controlled clinical trial evaluating the efficacy of VIB4920 combined with mycophenolate mofetil (MMF) and prednisone in achieving a renal response in participants with active lupus nephritis (LN).
Orange, California and other locations
Our lead scientists for Lupus research studies include Priyanka Iyer, MD Sheetal Desai.
Last updated: